上海市13价肺炎球菌多糖结合疫苗联合接种的安全性分析

Safety of simultaneous vaccination of 13-valent pneumococcal polysaccharide conjugate vaccine with other vaccines in Shanghai from 2017 to 2021

【目的】分析上海市13价肺炎球菌多糖结合疫苗(PCV13)单独接种和与其他疫苗联合接种后的安全性。【方法】通过中国免疫规划监测信息管理系统所收集的疑似预防接种异常反应(AEFI)中被动监测资料和上海市预防接种信息系统中接种PCV13的婴幼儿基本信息和疫苗使用资料,分析PCV13单独接种和同时与其他疫苗接种的AEFI报告发生率。【结果】PCV13单独接种892 329剂次,AEFI报告11 175例,AEFI报告发生率为1 252.34/10万;PCV13联合接种14 769剂次,AEFI报告215例,AEFI报告发生率为1 455.75例/10万。与PCV13联合接种最多的疫苗是口服轮状病毒减毒活疫苗(ORV),AEFI报告发生率为1 706.67/10万。PCV13单独接种和联合接种后AEFI报告均发热症状比例最高,报告发生率分别为876.69/10万和1 442.21/10万。【结论】相对单独接种,PCV13与其他部分疫苗联合接种增加了AEFI一般反应报告发生率,但尚可接受。

[Objective] To compare the incidence of adverse events following immunization(AEFI) between vaccination with 13-valent pneumococcal polysaccharide conjugate vaccine(PCV13)alone and with other vaccines at the same time.[Methods]We obtained PCV13 vaccination adverse reaction reports for children vaccinated in Shanghai between 2017-2021 from the National Immunization Program Information Management System and collected the information and the data of children vaccinated with PCV13 from The Shanghai vaccination information system. We compared the incidence of adverse reactions between stand-alone and simultaneous vaccination.[Results]A total of 11 175 PCV13 AEFI cases after stand-alone vaccination and 215 PCV13 AEFI cases after simultaneous vaccination were reported during 2017-2021 in Shanghai,and the incidence rates were 1 252.34/105and 1 455.75/105,respectively. ORV was the one mostly vaccinated with PCV13 at the same time,and the AEFI incidence was 1 706.67/105. The most reported symptom was fever after PCV13 vaccination,no matter by standalone and simultaneous vaccination with the respective incidence rates of 876.69/105 and 1 442.21/105.[Conclusion]In general,PCV13 vaccinated with other vaccines at the same time slightly increases the incidence of AEFI.